SCHEMBL801691

SCHEMBL801691

CCCc1cc(Nc2nc(-c3ccncc3)nc(-c3ccc(OC)cc3)n2)n[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.45
CHRNA7 P36544 3/20 0.44
ROCK2 O75116 2/20 0.43
GRK2 P25098 2/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.42
TGFBR1 P36897 1/20 0.41
IGF1R P08069 2/20 0.40
FGFR1 P11362 2/20 0.40
KDR P35968 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
GRK6 P43250 2/20 0.39
AURKA O14965 2/20 0.39
GSK3B P49841 2/20 0.39
SRC P12931 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801771 0.77 RET (0.40) IGF1RFGFR1KDRGRK6AURKA
SCHEMBL802363 0.75 AURKA (0.62) IGF1RFGFR1KDRAURKAGSK3B
SCHEMBL801690 0.72 PDE4B (0.48) ROCK2GRK2TGFBR1IGF1RGRK6
SCHEMBL801666 0.71 AURKA (0.67) IGF1RFGFR1KDRAURKAGSK3B
SCHEMBL13055178 0.71 AURKA (0.38) NPC1RAB9AIGF1RFGFR1KDR
SCHEMBL802079 0.67 AURKA (0.57) NPC1RAB9AIGF1RFGFR1KDR
SCHEMBL802292 0.66 AURKA (0.56) NPC1RAB9AIGF1RFGFR1KDR
SCHEMBL14423530 0.65 AURKA (0.49) IGF1RFGFR1KDRAURKAGSK3B
SCHEMBL338452 0.64 CLK4 (0.64) NPC1RAB9ACYP1A2KDM4EMEN1
SCHEMBL28827834 0.63 CHRNA7 (0.59) CHRNA7NPC1RAB9ACYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-8524720-B2 Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7951820-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-31 US disclosed
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-07 US disclosed
US-7691853-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-06 US disclosed
US-7390815-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-24 US disclosed
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, CDK3, GSK3A ABCG2 1614/4885CHRNA7 2965/4885ROCK2 60/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 ABCG2 2285/4885CHRNA7 1422/4885ROCK2 52/4885
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors GSK3B, CDK3, GSK3A ABCG2 1614/4885CHRNA7 2965/4885ROCK2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.